Medication Cost Inflation in 2026: Impact on Personal Injury Cases

James Wong — Founder & CEO, LienScripts | March 4, 2026 | 7 min read

Medication prices continue rising in 2026, increasing out-of-pocket costs for PI patients who rely on insurance. LienScripts pharmacy liens eliminate the cost barrier entirely by deferring medication expenses to settlement, regardless of inflation trends.

Medication cost inflation in 2026 continues to outpace general inflation, with brand-name drug list prices increasing at an average annual rate of 4-7% and specialty medication costs rising even faster. For personal injury plaintiffs, rising medication costs create larger out-of-pocket barriers when using insurance and higher overall lien amounts when medications are dispensed under pharmacy liens. Attorneys managing PI cases should understand how medication cost trends affect both client access and case economics. Pharmacy lien services through LienScripts insulate patients from cost inflation by eliminating upfront payment requirements entirely, ensuring that rising medication prices do not prevent injured plaintiffs from receiving prescribed treatment.

• Brand-name medication list prices are increasing 4-7% annually in 2026
• Specialty medication costs are rising at even higher rates, driven by biologic and complex drug pricing
• Rising costs increase patient copays and deductibles, creating larger barriers to medication access through insurance
• LienScripts pharmacy liens eliminate upfront costs regardless of medication price levels
• LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages

The 2026 Medication Cost Landscape

Medication pricing in 2026 reflects several converging trends:

Annual list price increases. Drug manufacturers continue to raise list prices on existing medications. While some manufacturers have pledged to limit annual increases, the aggregate trend remains upward.

New medication launches at premium prices. Newly approved medications enter the market at prices that reflect the manufacturer's assessment of clinical value, often at significant premiums to existing treatments.

Generic pricing stability with exceptions. Generic medication prices remain relatively stable overall, but certain generics in shortage or with limited competition have seen significant price increases.

Specialty and biologic cost growth. The fastest-growing category of medication costs is specialty and biologic drugs, which now account for over half of total drug spending despite representing a small fraction of total prescriptions.

According to James Wong, PharmD, founder of LienScripts, "Medication inflation hits PI patients twice. First, their insurance copays and deductibles are higher because drug prices are higher. Second, if they cannot afford those copays, they go without medications and their cases suffer. The pharmacy lien removes the price variable from the patient access equation."

How Inflation Affects PI Patient Access

Higher Out-of-Pocket Costs

As medication prices rise, insurance plans adjust by increasing copays, raising deductibles, and moving more medications to higher formulary tiers. A patient who could afford a $30 copay for a muscle relaxant in 2023 may face a $50 copay in 2026 for the same medication. For personal injury patients already dealing with lost wages and medical bills, these incremental increases can make medications unaffordable.

Formulary Changes

Insurers respond to cost inflation by narrowing formularies, removing higher-cost medications from coverage, and imposing more utilization management controls. Medications that were covered without restrictions in prior years may now require prior authorization or step therapy as insurers tighten cost controls.

Coverage Exclusions

Some insurers have implemented coverage exclusions for medication categories where costs have risen most aggressively. Personal injury patients may find that certain prescribed medications are no longer covered at all, requiring the prescriber to identify alternatives or the patient to pay the full price out of pocket.

Why Pharmacy Liens Are Inflation-Proof for Patients

The LienScripts pharmacy lien model is structurally insulated from medication cost inflation from the patient's perspective:

• The patient pays nothing upfront regardless of medication prices
• No copay, deductible, or coinsurance applies under the lien
• Medication access is determined by the prescriber's clinical order, not by insurance formulary economics
• Rising costs do not create access barriers because the lien defers all costs to settlement

This structure means that a personal injury patient receives the same level of medication access in a high-inflation year as in a low-inflation year. The cost is resolved at settlement, not at the pharmacy counter.

For attorneys advising clients on insurance-related medication access barriers, the pharmacy lien eliminates the entire category of cost-driven access problems.

Impact on Case Economics

Lien Amounts Reflect Current Pricing

Medication costs under the pharmacy lien reflect the actual prices at the time of dispensing. In an inflationary environment, this means lien amounts may be higher than they would have been for the same medications in prior years. Attorneys should anticipate this and prepare clients for the medication cost component of settlement discussions.

Defense Arguments About Pricing

Defense counsel may argue that medication prices are inflated or unreasonable. However, the prices reflected in the pharmacy lien are the actual market prices for medications at the time of dispensing. The MERIT report from LienScripts documents each dispensing with specificity, and the prices reflect real market conditions.

Settlement Allocation Planning

Attorneys should factor medication cost trends into settlement allocation planning. Cases that extend over longer treatment periods accumulate more medication costs, particularly for specialty drugs that see annual price increases. Early case resolution reduces total medication costs, while longer cases reflect the cumulative impact of price inflation.

For more on settlement allocation for pharmacy costs, the principles of medication cost allocation apply regardless of the inflation environment.

What Attorneys Can Do

Enroll Clients Immediately

The sooner a client enrolls in the pharmacy lien, the sooner cost barriers are eliminated. Waiting for insurance to process claims, deny coverage, or impose cost-sharing delays means the client faces current-year out-of-pocket costs that may be higher than they expect.

Monitor Treatment Duration

Work with treating providers to ensure treatment plans are clinically appropriate and efficiently managed. Unnecessary treatment extensions in an inflationary environment increase total medication costs without improving clinical outcomes.

Prepare for Pricing Discussions

Be prepared to discuss medication pricing in settlement negotiations. The MERIT report provides the documentation foundation, and understanding the market context of medication pricing in 2026 helps attorneys articulate why medication costs are what they are.

The Broader Trend

Medication cost inflation is a structural feature of the U.S. healthcare system, not a temporary aberration. For personal injury practice, this means that medication access through insurance will become progressively harder for patients, and pharmacy lien amounts will reflect progressively higher medication prices. Establishing pharmacy lien partnerships through LienScripts at the firm level ensures that every client has immediate medication access regardless of how the cost landscape evolves.